Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer

drug protocol number
1HN01
drug sponsor
King Fahad Medical City
drug study
Nimotuzumab
drug trial site
King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase